Blood Purification

Original Paper

Biocompatibility of Hemodialysis Membranes: Interrelations between Plasma Complement and Cytokine Levels

Varela M.P.a · Kimmel P.L.a · Phillips T.M.b · Mishkin G.J.a · Lew S.Q.a · Bosch J.P.a

Author affiliations

aDivision of Renal Diseases and Hypertension, Department of Medicine, and bImmunochemistry Laboratory, Department of Microbiology and Immunology, George Washington University Medical Center, Washington, D.C., USA

Keywords: Chronic renal diseasesHemodialysisInterleukin 1Interleukin 2ComplementC3aC5a

Related Articles for ""
Blood Purif 2001;19:370–379
https://doi.org/10.1159/000046967

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 20, 2001
Issue release date: 2001

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Hemodialysis (HD) membrane biocompatibility is defined as absence of complement activation. We have recently shown that circulating levels of interleukin (IL) 1 and IL-2 predict death and survival, respectively, of HD patients. Studies have assessed IL-1 in treatments with biocompatible and less biocompatible dialysis membranes, but no study has correlated circulating levels of all these immunoreactants. We assessed these immunoreactants, and temperature as an outcome, during HD in patients treated with different membranes. Twelve stable patients, receiving thrice-weekly chronic bicarbonate HD, were randomly dialyzed with three different types of membranes, composed of: Cuprophan, cuprammonium rayon modified cellulose, and Hemophan. Blood was drawn from the arterial line port before (Pre) and 15, 30, and 60 min during and after (Post) HD. Patients’ temperatures were measured before and after each treatment. The plasma concentrations of IL-1 and IL-2 and factors C3a and C5a were assessed by ELISA. There were no differences between baseline levels of any of the immunoreactants in patients treated with different dialyzers. C3a, C5a, and IL-1 levels increased significantly during HD treatments with all three different membranes. C3a, C5a, and IL-1 levels during Cuprophan and Hemophan treatments were significantly higher than the levels during modified cellulose treatment at 30 and 60 min and Post (p < 0.01). For all the immunoreactants, however, the Post levels were higher than the Pre levels. In contrast to IL-1, there were no differences in mean IL-2 levels during treatments when different membranes were compared. There were few correlations of plasma C3a and C5a levels with plasma IL-1 levels, but there was only one treatment time in one dialyzer group during which IL-2 and any of the other factors were correlated. Pre and Post temperature values and percent change in temperature were not correlated with any of the immunoreactants measured. These data show that C3a, C5a, and IL-1 responses are similar, but not identical, during treatments with different membranes. The response of circulating IL-2 levels to treatments is quite different from that of plasma C3a, C5a and IL-1 levels and suggests that these changes are not solely due to treatment factors. Treatment with modified cellulose membranes is associated with a different immunoreactive profile as compared with patients dialyzed using other cellulose membranes. We suggest that circulating IL-1 levels are good biocompatibility markers.

© 2001 S. Karger AG, Basel



Related Articles:

References

  1. Klinkman H, Wolf H, Schmitt E: Definition of biocompatibility; in Buccianti G (ed): Risk Profiles in Clinical Nephrology. Contrib Nephrol. Basel, Karger, 1984, vol 37, pp 70–77.
  2. Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990;1:150–161.
    External Resources
  3. Hakim RM , Schafer AI: Hemodialysis associated platelet activation and thrombocytopenia. Am J Med 1985;78:575–580.
    External Resources
  4. Basile C, Drüeke T: Dialysis membrane biocompatibility. Nephron 1989;52:113–118.
    External Resources
  5. Rosenkranz AR, Kormoczi GF, Thalhammer F, Menzel EJ, Hörl WH, Mayer G, Zlabinger GJ: Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. J Am Soc Nephrol 1999;10:128–135.
    External Resources
  6. Chenoweth DE, Cheung AK, Henderson LW: Anaphylatoxin formation during hemodialysis: Effects of different dialyzer membranes. Kidney Int 1983;24:764–769.
    External Resources
  7. Ing TS, Daugirdas JT, Popli S Gandhi VC: First-use syndrome with cuprammonium cellulose dialyzers. Int J Artif Organs 1983;6:235–239.
    External Resources
  8. Hakim RM, Breilatt J, Lazarus JM, Port FK: Complement activation and hypersensibility reactions to dialysis membranes. N Engl J Med 1984;311:878–882.
    External Resources
  9. Walton DF, Cheung AK: Membrane biocompatibility; in Nissenson AR, Fine RN, Gentile DE (eds): Clinical Dialysis, ed 3. Norwalk, Appleton & Lange, 1995, pp 93–120.
  10. Hakim RM: Choice of the hemodialysis membrane; in Henrich WL (ed): Principles and Practice of Dialysis. Baltimore, Williams & Wilkins, 1994, pp 1–7.
  11. Henderson LW, Koch KM, Dinarello CA, Shaldon S: Hemodialysis hypotension: The interleukin hypothesis. Blood Purif 1983;1:3–8.
    External Resources
  12. Dinarello CA, Koch KM, Shaldon S: Interleukin-1 and its relevance in patients treated with hemodialysis. Kidney Int 1985;33(suppl 24):21.
  13. Kimmel PL, Phillips TM, Phillips E, Bosch JP: Effect of renal replacement therapy on cellular cytokine production in patients with renal disease. Kidney Int 1990;38:129–135.
    External Resources
  14. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis J: Imunologic function and survival in hemodialysis patients. Kidney Int 1998;54:236–244.
    External Resources
  15. Bingel M, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Human interleukin-1 production during hemodialysis. Nephron 1986;43:161–163.
    External Resources
  16. Beltz M, Haensch G-M, Rautemberg E-W, Bommer J, Ritz E: Cuprammonium membranes stimulate interleukin-1 release and arachidonic acid metabolism in monocytes in the absence of complement. Kidney Int 1988;34:67–73.
    External Resources
  17. Bingel M, Lonnemann G, Koch KM, Dinarello CA, Shaldon S: Plasma interleukin-1 activity during HD: The influence of dialysis membranes. Nephron 1988;50:273–276.
    External Resources
  18. Luger A, Kovarik J, Stummvoll H-K, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production. Kidney Int 1987;32:84–88.
    External Resources
  19. Bosch JP, Mishkin GJ: Hemofiltration and double high flux dialysis: Risks and benefits. Curr Opin Nephrol Hypertens 1998;7:643–647.
    External Resources
  20. Klos A, Ihrig V, Messner M, Grabbe J, Bitter-Suermann D: Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISA with monoclonal antibodies. J Immunol Methods 1988;111:241–252.
    External Resources
  21. Thorpe GH, Bronstein I, Kricka LJ, Edwards B, Voyta JC: Chemiluminescent enzyme immunoassay of α-fetoprotein based on an adamantyl dioxetane phenyl phosphate substrate. Clin Chem 1989;35:2319–2321.
    External Resources
  22. Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L: Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996;50:566–570.
    External Resources
  23. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor. Kidney Int 1990;37:116–125.
    External Resources
  24. Haeffner-Cavaillon N, Cavaillon J-M, Ciancioni C, Bacle F, Delons S, Katzatchkine MD: In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989;35:1212–1218.
    External Resources
  25. Cheung AK, Parker CJ, Wilcox L, Janatova J: Activation of the alternative pathway of complement by hemodialysis membranes. Kidney Int 1989;36:257–265.
    External Resources
  26. Lhotta K, Wurzner R, Kronenberg F, Oppermann M, Koning P: Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int 1998;53:1044–1051.
    External Resources
  27. US Renal Data System: USRDS Annual Data Report. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
  28. Hakim RM: Complement activation by biomaterials. Cardiovasc Pathol 1993;2(suppl):187.
  29. Hiyoshi T, Shirokaze J: Polyethylene-glycol chain (PEG chain) grafted cellulosic membrane: Characterization of clinical biocompatibility and mechanism of biocompatibility (abstract). J Am Soc Nephrol 1998;9:173.
  30. Skubitz KM, Craddock PR: Reversal of hemodialysis granulocytopenia and pulmonary leukostasis. J Clin Invest 1981;67:1383–1391.
    External Resources
  31. Cheung AK, Chenoweth DE, Otsuka D, Henderson L: Compartmental distribution of complement activation products in artificial kidneys. Kidney Int 1986;30:74–80.
    External Resources
  32. Ivanovich P, Chenoweth DE, Schmidt R, Klinkmann H, Boxer LA, Jacob HS, Hammerschmidt DE: Symptoms and activation of granulocytes and complement with two dialysis membranes. Kidney Int 1983;24:758–763.
    External Resources
  33. Pereira BJG, Snodgrass BR, Hogan PJ, King AJ: Diffusive and convective transfer of cytokine-inducing bacterial products across hemodialysis membranes. Kidney Int 1995;47:603–610.
    External Resources
  34. Haag-Weber M, Mai B, Deppisch R, Gohl H, Hörl WH: Studies of biocompatibility of different dialyzer membranes: Role of complement system, intracellular calcium and inositol-triphosphate. Clin Nephrol 1994;41:245–251.
    External Resources
  35. Falkenhagen D, Bosch T, Brown GS, Schmidt B, Holtz M, Baurmeister U, Gurland H, Klinkmann H: A clinical study on different cellulosic dialysis membranes. Nephrol Dial Transplant 1987;2:537–545.
    External Resources
  36. Deppisch R, Schmitt V, Bommer J, Hansch GM, Ritz E, Rauterberg EW: Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990;37:696–706.
    External Resources
  37. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990;37:85–93.
    External Resources
  38. Laude-Sharp M, Caroff M, Simard L, Pulineri C, Kazatchkine MD, Haeffner-Cavaillon N: Induction of IL-1 during hemodialysis: Transmembrane passage of intact endotoxins (LPS). Kidney Int 1990;38:1089–1094.
    External Resources
  39. Bingel M, Lonnemann G, Koch KM: Enhancement of in vitro human interleukin-1 production by sodium acetate. Lancet 1987;i:14–16.
  40. Kimmel PL, Phillips TM, Lew SQ, Langman CB: Zinc modulates mononuclear cellular calcitriol metabolism in peritoneal dialysis patients. Kidney Int 1996;49:1407–1412.
    External Resources
  41. Dinarello CA: Cytokines: Agents provocateurs in hemodialysis? Kidney Int 1992;41:683–694.
    External Resources
  42. Haeffner-Cavaillon N, Cavaillon JM, Laude M, Kazatchkine MD: C3a (C3adesArg) induces production and release of interleukin 1 by cultured human monocytes. J Immunol 1987;139:794–799.
    External Resources
  43. Ronco C: Hemofiltration and hemodiafiltration; in Bosch JP, Stein JH (eds): Hemodialysis High-Efficiency Treatments. Contemp Issues Nephrol. New York, Churchill Livingstone, 1993, vol 27, pp 119–133.
  44. Canivet E, Lavaud S, Wong T, Guénounou M, Willemin JC, Potron G, Chanard J: Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1991;23:41–46.
  45. Port FK, Van De Kerkhove KM, Kunkel SL, Kluger MJ: The role of dialysate in the stimulation of interleukin-1 production during clinical hemodialysis. Am J Kidney Dis 1987;10:118–122.
    External Resources
  46. Blumenstein M, Schmidt B, Ward RA, Ziegler-Heitbrock HWL, Gurland HJ: Altered interleukin-1 production in patients undergoing hemodialysis. Nephron 1988;50:277–281.
    External Resources
  47. Dinarello CA, Mier JW: Current concepts. Lymphokines. N Engl J Med 1986;317:940–945.
  48. Atkins E, Bodel P: Fever. N Engl J Med 1972;286:27–34.
    External Resources
  49. Beaurain G, Naret C, Marcon L: In vivo T cell preactivation in chronic uremic hemodialyzed and nonhemodialyzed patients. Kidney Int 1989;36:636–644.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: September 20, 2001
Issue release date: 2001

Number of Print Pages: 10
Number of Figures: 2
Number of Tables: 1

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2001, Vol.19, No. 4

2001

Article

Recommend This
TOP